The dynamics of DNA methylation in schizophrenia and related psychiatric disorders

Neuropsychopharmacology

Volumn 38, Issue 1, 2013, Pages 138-166

  Grayson, Dennis R ^a   Guidotti, Alessandro ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

animal models; antipsychotics; chromatin; DNA methylation; hydroxymethylation; nicotine

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CELL DNA; CLOZAPINE; DNA METHYLTRANSFERASE; DOPAMINE 2 RECEPTOR; GLUTAMATE DECARBOXYLASE 67; HALOPERIDOL; HOMOCYSTEINE; MESSENGER RNA; METHIONINE; OLANZAPINE; QUETIAPINE; REELIN; RISPERIDONE; SULPIRIDE; VALPROIC ACID;

BIPOLAR DISORDER; CARBON METABOLISM; DEMETHYLATION; DNA DEMETHYLATION; DNA HYDROXYMETHYLATION; DNA METHYLATION; EPILEPSY; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HISTONE MODIFICATION; HUMAN; HYPERHOMOCYSTEINEMIA; IMMOBILIZATION STRESS; MENTAL DISEASE; MENTAL PATIENT; MOLECULAR DYNAMICS; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SCHIZOPHRENIA;

ANIMALS; BRAIN CHEMISTRY; DNA METHYLATION; GABAERGIC NEURONS; HUMANS; MENTAL DISORDERS; PROTEIN BINDING; SCHIZOPHRENIA;

EID: 84869087636     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.125     Document Type: Review

References (73)

1. Aapola U, Kawasaki K, Scott HS, Ollila J, Vihinen M, Heino M et al (2000). Isolation and initial characterization of a novel zinc finger gene, DNMT3L, on 21q22.3, related to the cytosine-5-methyltransferase 3 gene family. Genomics 65: 293-298.
2. Aapola U, Lyle R, Krohn K, Antonarakis SE, Peterson P (2001). Isolationand initial characterization of the mouse Dnmt3l gene. Cytogenet Cell Genet 92: 122-126.
3. Abdolmaleky HM, Cheng KH, Faraone SV, Wilcox M, Glatt SJ, Gao F et al (2006). Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet 15: 3132-3145.
4. Abdolmaleky HM, Cheng KH, Russo A, Smith CL, Faraone SV, Wilcox M et al (2005). Hypermethylation of the reelin (RELN). promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 134: 60-66.
5. Abdolmaleky HM, Thiagalingam S (2011) Can the schizophrenia epigenome provide clues for the molecular basis of pathogenesis? Epigenomics 3: 679-683.
6. Adler Nevo G, Meged S, Sela BA, Hanoch-Levi A, Hershko R, Weizman A (2006). Homocysteine levels in adolescent schizophrenia patients. Eur Neuropsychopharmacol 16: 588-591.
7. Akbarian S, Huang H-S (2006). Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res Rev 52: 293-304.
8. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney Jr WE et al (1995). Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 52: 258-266.
9. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW (2009). Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 89: 73-120.
10. Allen MD, Grummitt CG, Hilcenko C, Min SY, Tonkin LM, Johnson CM et al (2006). Solution structure of the nonmethyl-CpG-binding CXXC domain of the leukaemia-associated MLL histone methyltransferase. EMBO J 25: 4503-4512.
11. Amann LC, Gandal MJ, Halene TB, Ehrlichman RS, White SL, McCarren HS et al (2010). Mouse behavioral endophenotypes for schizophrenia. Brain Res Bull 83: 147-161.
12. Andria ML, Simon EJ (1999). Localization of promoter elements in the human muopioid receptor gene and regulation by DNA methylation. Brain Res Mol Brain Res 70: 54-65.
13. Anier K, Malinovskaja K, Aonurm-Helm A, Zharkovsky A, Kalda A (2010). DNA methylation regulates cocaine-induced behavioral sensitization in mice. Neuropsychopharmacology 35: 2450-2461.
14. Applebaum J, Shimon H, Sela BA, Belmaker RH, Levine J (2004). Homocysteine levels in newly admitted schizophrenic patients. J Psychiatr Res 38: 413-416.
15. Araujo FD, Croteau S, Slack AD, Milutinovic S, Bigey P, Price GB et al (2001). The DNMT1 target recognition domain resides in the N terminus. J Biol Chem 276: 6930-6936.
16. Auta J, Longone P, Guidotti A, Costa E (1999). The regulation of hippocampal nicotinic acetylcholine receptors (nAChRs). after a protracted treatment with selective or nonselective nAChR agonists. J Mol Neurosci 13: 31-45.
17. Ayton PM, Chen EH, Cleary ML (2004). Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein. Mol Cell Biol 24: 10470-10478.
18. Bannister AJ, Kouzarides T (2011). Regulation of chromatin by histone modifications. Cell Res 21: 381-395.
19. Barreto G, Schäfer A, Marhold J, Stach D, Swaminathan SK, Handa V et al (2007). Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature 445: 671-675.
20. Baylin SB, Herman JG (2000). DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16: 168-174.
21. Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y et al (2010). Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nature Neurosci 13: 76-83.
22. Benes FM, Lim B, Subburaju S (2009). Site-specific regulation of cell cycle and DNA repair in post-mitotic GABA cells in schizophrenic versus bipolars. Proc Natl Acad Sci USA 106: 11731-11736.
23. Bhattacharya SK, Ramchandani S, Cervoni N, Szyf M (1999). A mammalian protein with specific demethylase activity for mCpG DNA. Nature 397: 579-583.
24. Bhutani N, Burns DM, Blau HM (2011). DNA demethylation dynamics. Cell 146: 866-872.
25. Bird A (2002). DNA methylation patterns and epigenetic memory. Genes Dev 16: 6-21.
26. Bird A (2011). Putting the DNA back into DNA methylation. Nat Genet 43: 1050-1051.
27. Blackledge NP, Zhou JC, Tolstorukov MY, Farcas AM, Park PJ, Klose RJ (2010). CpG islands recruit a histone H3 lysine 36 demethylase. Mol Cell 38: 179-190.
28. Booth MJ, Branco MR, Ficz G, Oxley D, Krueger F, Reik W et al (2012). Quantitative sequencing of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution. Science 336: 934-937.
29. Bransteitter R, Prochnow C, Chen XS (2009). The current structural and functional understanding of APOBEC deaminases. Cell Mol Life Sci 66: 3137-3147.
30. Breese CR, Lee MJ, Adams CE, Sullivan B, Logel J, Gillen KM et al (2000). Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 23: 351-364.
31. Bromberg A, Levine J, Belmaker R, Agam G (2011). Hyperhomocysteinemia does not affect global DNA methylation and nicotinamide N-methyltransferase expression in mice. J Psychopharmacol 25: 976-981.
32. Bromberg A, Levine J, Nemetz B, Belmaker RH, Agam G (2008). No association between global leukocyte DNA methylation and homocysteine levels in schizophrenia patients. Schizophr Res 101: 50-57.
33. Brown AS (2011). The environment and susceptibility to schizophrenia. Prog Neurobiol 93: 23-58.
34. Brown AS, Bottiglieri T, Schaefer CA, Quesenberry Jr CP, Liu L, Bresnahan M et al (2007). Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch Gen Psychiatry 64: 31-39.
35. Brown AS, Patterson PH (2011). Maternal infection and schizophrenia: implications for prevention. Schizophr Bull 37: 284-290.
36. Brown RW, Gonzalez CL, Kolb B (2000). Nicotine improves Morris water task performance in rats given medial frontal cortex lesions. Pharmacol Biochem Behav 67: 473-478.
37. Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC et al (2011). A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry 69: 442-449.
38. Cardoso MC, Leonhardt H (1999). DNA methyltransferase is actively retained in the cytoplasm during early development. J Cell Biol 147: 25-32.
39. Casey DE, Daniel DG, Tamminga C, Kane JM, Tran-Johnson T, Wozniak P et al (2009). Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology 34: 1330-1338.
40. Chao HT, Chen H, Samaco RC, Xue M, Chahrour M, Yoo J et al (2010). Dysfunction in GABA signaling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 468: 263-269.
41. Chapman A, Keane PE, Meldrum BS, Simiand J, Vernieres JC (1982). Mechanism of anticonvulsant action of valproate. Prog Neurobiol 19: 315-359.
42. Chédin F (2011). The DNMT3 family of mammalian de novo DNA methyltransferases. Prog Mol Biol Transl Sci 101: 255-285.
43. Chédin F, Lieber MR, Hsieh CL (2002). The DNA methyltransferase- like protein DNMT3L stimulates de novo methylation by Dnmt3a. Proc Natl Acad Sci USA 99: 16916-16921.
44. Chen Y, Dong E, Grayson DR (2011). Analysis of the GAD1 promoter: trans-acting factors and DNA methylation converge on the 50 untranslated region. Neuropharmacology 60: 1075-1087.
45. Chen Y, Kundakovic M, Agis-Balboa RC, Pinna G, Grayson DR (2007). Induction of the reelin promoter by retinoic acid is mediated by Sp1. J Neurochem 103: 650-665.
46. Chen Y, Sharma RP, Costa RH, Costa E, Grayson DR (2002). On the epigenetic regulation of human reelin promoter expression. Nucleic Acids Res 30: 2930-2939.
47. Chen ZX, Riggs AD (2011). DNA methylation and demethylation in mammals. J Biol Chem 286: 18347-18353.
48. Choi SH, Heo K, Byun HM, An W, Lu W, Yang AS (2011). Identification of preferential target sites for human DNA methyltransferases. Nucleic Acids Res 39: 104-118.
49. Chuang LS, Ian HI, Koh TW, Ng HH, Xu G, Li BF (1997). Human DNA-(cytosine-5). methyltransferase-PCNA complex as a target for p21WAF1. Science 277: 1996-2000.
50. Citrome L (2003). Schizophrenia and valproate. Psychopharmacol Bull 37(Suppl 2): 74-88.
51. Citrome L, Tremeau F, Wynn PS, Roy B, Dinakar H (2004). A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia. J Clin Psychopharmacol 24: 255-259.
52. Clements EG, Mohammad HP, Leadem BR, Easwaran H, Cai Y, Van Neste L et al (2012). DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymes. Nucleic Acids Res 40: 4334-4346.
53. Cohen SM, Nichols A, Wyatt R, Pollin W (1974). The administration of methionine to chronic schizophrenic patients: a review of ten studies. Biol Psychiatry 8: 209-225.
54. Cortellino S, Xu J, Sannai M, Moore R, Caretti E, Cigliano A et al (2011). Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 146: 67-79.
55. Costa E, Chen Y, Davis J, Dong E, Noh JS, Tremolizzo L et al (2002). Reelin and schizophrenia: a disease at the interface of the genome and the epigenome. Mol Interventions 2: 47-57.
56. Costa E, Chen Y, Dong E, Grayson DR, Kundakovic M, Maloku E et al (2009). GABAergic promoter hypermethylation as a model to study the neurochemistry of schizophrenia vulnerability. Expert Rev Neurother 9: 87-98.
57. Costa E, Davis J, Grayson DR, Guidotti A, Pappas GD, Pesold C (2001). Dendritic spine hypoplasticity and downregulation of reelin and GABAergic tone in schizophrenia vulnerability. Neurobiol Dis 8: 723-742.
58. Costa E, Dong E, Grayson DR, Guidotti A, Ruzicka W, Veldic M (2007). Reviewing the role of DNA (cytosine-5) methyltransferase overexpression in the cortical GABAergic dysfunction associated with psychosis vulnerability. Epigenetics 2: 29-36.
59. Costa E, Dong E, Grayson DR, Ruzicka WB, Simonini MV, Veldic M et al (2006). Epigenetic targets in GABAergic neurons to treat schizophrenia. Adv Pharmacol 54: 95-117.
60. Costa E, Grayson DR, Guidotti A (2003). Epigenetic downregulation of GABAergic function in schizophrenia vulnerability: potential for pharmacological intervention. Mol Interventions 3: 220-229.
61. Creveling CR, Daly JW (1967). Identification of 3,4- dimethoxyphenethylamine from schizophrenic urine by mass spectrometry. Nature 216: 190-191.
62. Day JJ, Sweatt JD (2012). Epigenetic treatments for cognitive impairments. Neuropsychopharmacology 37: 247-260.
63. Deaton AM, Bird A (2011). CpG islands and the regulation of transcription. Genes Dev 25: 1010-1022.
64. Dempster EL, Pidsley R, Schalkwyk LC, Owens S, Georgiades A, Kane F et al (2011). Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet 20: 4786-4796.
65. Detich N, Bovenzi V, Szyf M (2003). Valproate induces replication-independent active DNA demethylation. J Biol Chem 278: 27586-27592.
66. Dhe-Paganon S, Syeda F, Park L (2011). DNA methyl transferase 1: regulatory mechanisms and implications in health and disease. Int J Biochem Mol Biol 2: 58-66.
67. Dierker L, Donny E (2008). The role of psychiatric disorders in the relationship between cigarette smoking and DSM-IV nicotine dependence among young adults. Nicotine Tob Res 10: 439-446.
68. Dohi O, Takada H, Wakabayashi N, Yasui K, Sakakura C, Mitsufuji S et al (2010). Epigenetic silencing of RELN in gastric cancer. Int J Oncol 36: 85-92.
69. Dong E, Agis-Balboa RC, Simonini MV, Grayson DR, Costa E, Guidotti A (2005). Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia. Proc Natl Acad Sci USA 102: 12578-12583.
70. Dong E, Chen Y, Gavin DP, Grayson DR, Guidotti A (2010). Valproate induces DNA demethylation in nuclear extracts from adult mouse brain. Epigenetics 5: 730-735.
71. Dong E, Gavin DP, Chen Y, Davis J (2012). Up-regulation of TET1 and downregulation of APOBEC3A and APOBEC3C in the parietal cortex of psychotic patients. Translational Psychiatry, in press.
72. Dong E, Grayson DR, Guidotti A, Costa E (2009). Antipsychotic subtypes can be characterized by differences in their ability to modify GABAergic promoter methylation. Epigenomics 1: 201-211.
73. Dong E, Guidotti A, Grayson DR, Costa E (2007). Demethylation of reelin and glutamic acid decarboxylase 67 brain promoters is induced by hyperacetylation of histones. Proc Natl Acad Sci USA 104: 4676-4681.